<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109625</url>
  </required_header>
  <id_info>
    <org_study_id>38RC.19.159</org_study_id>
    <nct_id>NCT04109625</nct_id>
  </id_info>
  <brief_title>Preliminary Validation of an in Vitro Diagnosis-medical Device for Hepatitis B Screening</brief_title>
  <acronym>DiVHeB</acronym>
  <official_title>Preliminary Validation of the Demonstrator of an In Vitro Diagnostic Device for Hepatitis B Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>magIA Diagnostics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principale objective of the study is to perform a first step of technical adjustment and
      preliminary validation of a diagnostic test for hepatitis B (HBsAntigen, anti-HBs Antibody
      and anti-HBc Antibody) on capillary blood with the device under study in non-immunized
      subjects against hepatitis B, in subjects with hepatitis B, in subjects with old or cured
      hepatitis B and in hepatitis B vaccine recipients, compared with the values obtained with the
      reference technique of medical biology laboratory on serum. The analysis will be performed on
      the entire cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis of hepatitis B in precarious populations is often difficult. The use of a in
      vitro diagnosis-medical device in point of care could alleviate this difficulty. It would
      identify whether or not the subjects are infected with the virus, whether they are immunized
      or not. Then, depending on the results, the subjects could be directly vaccinated or referred
      to a laboratory of medical biology for confirmation / invalidation of the diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>4 parallel groups of 10 volunteers</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasability of correlation</measure>
    <time_frame>Day 0</time_frame>
    <description>To evaluate the feasability estimated by correlation of the measurements (HBsAg, anti-HBs Ab, HBc-Ab) between the IVD-MD in point of care on capillary blood study and the laboratory results obtained on serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>repetability of the measurement HBsAg, anti-HBs Ab, HBc-Ab</measure>
    <time_frame>day 0</time_frame>
    <description>Comparison of the repeatability of the measurement of HBsAg, anti-HBs Ab, HBc-Ab on 2 different fingers with the same device and the same batch of consumables with 2 different times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reproductibility of the measurement HBsAg, anti-HBs Ab, HBc-Ab</measure>
    <time_frame>day 0</time_frame>
    <description>Comparison of the reproducibility of HBsAg, anti-HBs Ab, HBc-Ab via a test from 2 drops of blood on 2 different fingers with 2 different cartridges and two different readers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation according to status</measure>
    <time_frame>day 0</time_frame>
    <description>Comparison of the correlation coefficients of the measurements between the IVD-MD in point of care and the biology automaton according to the different statuses</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Healthy</condition>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Non-immunized Hepatitis B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects non-immunized against hepatitis B (naive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine Hepatitis B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects vaccinated against hepatitis B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Old or cured Hepatitis B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with hepatitis B (old or cured)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ongoing Hepatitis B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with hepatitis B (ongoing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DÃ©monstrateur MAGIA</intervention_name>
    <description>test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.</description>
    <arm_group_label>Non-immunized Hepatitis B</arm_group_label>
    <arm_group_label>Old or cured Hepatitis B</arm_group_label>
    <arm_group_label>Ongoing Hepatitis B</arm_group_label>
    <arm_group_label>Vaccine Hepatitis B</arm_group_label>
    <other_name>v0.1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: HBsAg negative, Anti HBc negative, Anti HBs negative, during a laboratory
             assay on serum

          -  Group 2: HBsAg negative, Anti HBc negative, Anti HBs positive, during a laboratory
             assay on serum

          -  Group 3: HBsAg negative, Anti HBc positive, Ab anti HBs positive or negative, during a
             laboratory assay on serum

          -  Group 4: HBsAg positive, Anti HBc positive, Anti HBs negative, during a laboratory
             assay on serum

          -  all: affiliated to social security or beneficiary of such a scheme

        Exclusion Criteria:

          -  Infection by a confounding factor: HIV, HCV and / or HDV

          -  Protected person: Pregnant woman, parturient, mother who is breastfeeding, person
             deprived of liberty by judicial or administrative decision, person subject to a legal
             protection measure

          -  Exclusion period for other research studies involving the human person

          -  Annual threshold of allowances for participation in research involving the affected
             human person.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc CRACOWSKI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grenoble Alps University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Kauffmann, PhD</last_name>
    <phone>+33 4 76 75 46 00</phone>
    <email>paul.kauffmann@magia-diagnostics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Delshadi, PhD</last_name>
    <phone>+33 4 76 75 46 00</phone>
    <email>sarah.delshadi@magia-diagnostics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical research center CIC1406</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline Paris, PharmD, PhD</last_name>
      <phone>+33 4 76 76 73 83</phone>
      <email>aparis@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

